IL-12 TAVO
Intratumoral
Cancer Immunotherapy

Learn More About TAVO™

Updated: Corporate Presentation

ROTH Conference Webcast     KEYNOTE-695 SITC Poster

TAVO Demonstration     SABCS Posters

Clinical trials of today may power
the medical advances of tomorrow.

Learn more about our current clinical trials:

Advanced Melanoma     Triple Negative Breast Cancer

Spotlight 

Nature Gene Therapy: Characterization of abscopal effects of intratumoral electroporation-mediated IL-12 gene therapy

Immuno-Oncology News: TAVO reverses resistance to PD-1 inhibitors in metastatic melanoma, phase 2b trial suggests

Health Professionals Radio: President and CEO Dan O’Connor discusses late-stage studies in melanoma and TNBC.

News & Events

Mar 13, 2019
OncoSec to Present at the 31st Annual ROTH Conference
Feb 28, 2019
OncoSec Announces Poster Presentation at 2019 American Association for Cancer Research Annual Meeting
Feb 8, 2019
OncoSec To Present At BIO CEO & Investor Conference
Feb 1, 2019
OncoSec Provides KEYNOTE-695 Clinical Update And Outlines 2019 Milestones

Tavokinogene Telseplasmid “TAVO”

Taking the fight directly to the tumor

Through the intratumoral administration of IL-12, our lead product candidate, TAVO, may stimulate a safe but powerful systemic immune response leading to an innovative and potentially transformative therapy option for the treatment of cancer.

Learn More

Arming the Immune System to Fight Cancer

Clinical Pipeline

Pipeline
Our core technology platform continues to advance through clinical trials for various cancers.

Learn More

Technology

Technology
The Intratumoral IL-12 platform is designed to boost the immune system to recognize and attack tumors.

Learn More

Collaborators

Collaborators
OncoSec continues to establish relationships with industry leaders to further advance our research.

Learn More

IN THE CLINIC

Watch the Video

EXPLORE OUR TECHNOLOGY

Watch the Video

GUIDED BY SCIENCE

Visit the Site